Alto Neuroscience raises $120 million in a Private Placement Financing led by Commodore Capital to support the development of ALTO-207 for Treatment Resistant Depression.
Amount Raised
$120 Million
Round Type
Post-IPO Equity
Mountain ViewBiotechnologyHealth CareInvestors
Description
Alto Neuroscience, Inc. announced a securities purchase agreement for approximately $120 million through a private placement financing. The financing is led by Commodore Capital with participation from several investors. Funds will support the development of ALTO-207 in a planned Phase 3 trial for treatment resistant depression
Quick answer
Alto Neuroscience raised $120 Million in a Post-IPO Equity round, dated March 16, 2026. Investors: Venrock Healthcare Capital Partners, Vestal Point Capital, Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital and Commodore Capital. Alto Neuroscience is based in Mountain View, California, United States.
- How much did Alto Neuroscience raise?
- Alto Neuroscience raised $120 Million in a Post-IPO Equity round on March 16, 2026.
- Who invested in Alto Neuroscience?
- Venrock Healthcare Capital Partners, Vestal Point Capital, Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital and Commodore Capital are named as investors in this round.
- What does Alto Neuroscience do?
- Alto Neuroscience is a biopharmaceutical company redefining psychiatry through its Precision Psychiatry Platform™, which leverages individuals’ neurobiology to develop personalized and highly effective medicines that..
- Where is Alto Neuroscience based and how big is it?
- Alto Neuroscience is based in Mountain View, California, United States. Fundz records about 76 employees.
- Who are the decision-makers at Alto Neuroscience?
- Fundz holds 2 contacts at Alto Neuroscience, including the VP of Translational Medicine. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Alto Neuroscience that raised within 45 days of this round, from Fundz verified event records.
- Shuttle Pharmaceuticals Holdings raised $10M on April 30, 2026.
- Auxilium Health raised $3.4M (Seed) on April 30, 2026.
- Moleculent AB raised $20M (Funding Round) on April 30, 2026.
- Iterative Health raised $77M (Series C) on April 30, 2026.
- Tacalyx raised $13M (Seed) on April 29, 2026.
- mbiomics raised $35M (Series A) on April 29, 2026.
Who to call at Alto Neuroscience, and when
A new round usually means Alto Neuroscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alto Neuroscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alto Neuroscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alto Neuroscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alto Neuroscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Alto Neuroscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.